Entering text into the input field will update the search result below

$12 Billion US market drug of CLDA approved by FDA , will be worth even more Multi-Billions Worldwide.

Jan. 24, 2011 9:55 AM ETCLDA, DNDN, MRK, PFE, LLY, BIIB
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$CLDA biotech ready to turn into EPS Momentum type stock with FDA approval. http://tinyurl.com/6zkn8cp

Clinical Data (CLDA 23.80) initiated with a Mkt Outperform at Rodman & Renshaw; tgt $46. Firm believes that Viibryd's unique safety profile holds a substantial commercial potential and that Clinical Data may be an attractive acquisition target for large pharmaceutical companies. Firm estimates that Viibryd may reach a blockbuster status of $1B in annual sales within four years of launch, which we believe is reasonable based on the reported revenue for other recently launched antidepressants. Additionally, firm sees potential upside to their target price from a more successful launch, potential label expansion into other psychiatric indications for Viibryd, as well as the clinical and commercial success of Stedivaze, a Phase 3 drug that they did not include in the current valuation.

$CLDA barely trading +3/shr higher than Oct. high $20 Upside is huge there was no prior FDA approval run here, actually it was a sellof prior to the FDA news. Shorts were expecting FDA rejection and caused shares to selloff from $20 to low teens.


According to articles I have been reading: Viibryd will have $1+ Billion potential sales in USA alone. Once approved in other countries (other nations usually follow US FDA path) The potential sales will be in the multi billions per year worldwide. But for now the drug is entering a $12 billion market in the USA.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.